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Canine disease modelThe processes regulating the complex neurodegenerative cascade of vacuolation, neuroinﬂammation,
neuronal loss and myelin deﬁcits in fucosidosis, a neurological lysosomal storage disorder, remain unclear. To
elucidate these processes the gene expression proﬁle of the cerebral cortex from untreated and intrathecal
enzyme replacement therapy treated fucosidosis pups and age-matched unaffected controls were examined.
Neuroinﬂammation and cell death processes were identiﬁed to have a major role in fucosidosis
pathophysiology with 37% of differentially expressed (DE) genes involved in these processes. Critical,
speciﬁc, early decreases in expression levels of key genes in myelin assembly were identiﬁed by gene
expression proﬁling, including myelin-associated glycoprotein (MAG), myelin and lymphocyte protein (MAL),
and oligodendrocyte myelin paranodal and inner loop protein (OPALIN). These gene expression changes may
be indicative of early neuronal loss causing reduced electrical impulses required for oligodendrocyte
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Lysosomal storage diseases (LSDs) are a group of severe and
rapidly progressive inherited disorders caused by defects in lysosomal
processing and trafﬁcking. The accumulation of undegraded sub-
strates within lysosomes produces characteristic storage inclusions in
many disorders [1]. Fucosidosis, a neurological LSD that afﬂicts both
humans and dogs, is caused by mutations in the FUCA1 gene that
result in a deﬁciency of α-L-fucosidase enzyme activity [2,3]. This
deﬁciency impairs the catabolism of fucosylated glycoproteins and
results in glycoprotein storage within lysosomes [4].Fucosidosis in English Springer spaniel dogs is a homolog and the
only preserved animal model for human fucosidosis [5]. Behavioral
changes are noticed from 4 to 6 months, with progressive mental
deterioration and neurological decline indicative of frontal cortex
dysfunction from 8 to 12 months, which leads to euthanasia by 3 years
of age [6]. Vacuolation in the frontal cortex of affected pups occurs by
2 months of age and begins before onset of clinical signs [7,8]. Early
vacuolation is accompanied by a neuroinﬂammatory responsemediated
by astrocytes andmicroglia, and subtlemyelin deﬁcitswhich develop by
4 months, worsening as the disease continues [7,8]. Progressive disease
is common to other LSDs including Sandhoff disease [9] and the
glycoproteinoses α- and β-mannosidosis [10–12] where vacuolation is
also accompanied by neuroinﬂammation and hypomyelination.
It is unclear what processes drive disease progression from early
vacuolation andneuroinﬂammation to irreversible neuronal andmyelin
loss in late fucosidosis and other LSDs. Vacuolation is believed to disrupt
normal extracellular trafﬁc and appears to activate microglia, resulting
in a dysregulated, destructive inﬂammatory response, particularly in the
brain. In Sandhoff disease, chronic neuroinﬂammation has been linked
to neuronal loss through the secretion of the pro-apoptotic cytokine,
tumor necrosis factor-alpha (TNFα) by microglia [9]. The neuronal loss
evident in fucosidosis pups at 4 months [7,8] is accompanied by
microgliosis and astrogliosis and may be initiated by pro-apoptotic
cytokines, but this has yet to be demonstrated. Early neuronal loss
reduces axonal activity and may also lead to oligodendrocyte (OL) loss
with consequent myelin deﬁcits [13,14].
Intrathecal enzyme replacement therapy (IT-ERT) is a developing
treatment for LSDs with central nervous system (CNS) involvement. It
involves the direct infusion of a recombinant functional form of the
Table 2
Primers for qRT-PCR.
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IT-ERT signiﬁcantly reduced the level of fucosylated oligosaccharide
accumulation in the brain, improved clinical signs and there was a non-
some reduction of secondary neuropathology in treated animals [16]
(Kondagari, unpublished data). That secondary changes were less
responsive to treatment, despite signiﬁcant storage reductions, further
demonstrates the need to understand the mechanisms that trigger
neuroinﬂammation, and neuronal andmyelin loss after initial storage to
improve therapeutic regimes for LSDs.
To elucidate the neuropathological processes involved in fucosidosis,
the present study examined the gene expression proﬁle of the cerebral
cortex from untreated and IT-ERT treated fucosidosis and unaffected
pups. Microarray analysis can be used to identify changes in the
trancriptomes between normal and disease states and has been used to
identify neuroinﬂammatory mediators in Sandhoff disease [9] and
transcriptional alterations of lysosomal biogenesis genes inmucolipidosis
IV [17]. Here, we report downregulation of OL andmyelin-speciﬁc genes
in 4 month old fucosidosis pups and propose a model of fucosidosis
pathogenesis that is consistent with hypomyelination caused by a defect
in OL maturation, as the mechanism of poor myelination in fucosidosis.
2. Materials and methods
2.1. Sample collection and preparation
Brains from 4 month old fucosidosis-affected and age-matched
related control English Springer spaniel pups were collected at
necropsy. Animals had been involved in an enzyme replacement
therapy trial, where affected animals received at 8, 12 and 16 weeks of
age infusions of recombinant canine α-L-fucosidase (AET, n=3) or
the phosphate buffered saline (PBS) vehicle (AVT, n=3) via the
cisterna magna. Unaffected age-matched controls (CVT, n=3)
received monthly intracisternal infusions of the PBS vehicle only
[16]. The allocation of animals for each treatment is outlined in
Table 1. All procedures were approved by the Animal Ethics
Committee at the University of Sydney and Westmead Hospital and
followed the Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purposes.
Frontal cortex tissue for microarray analysis was snap frozen and
stored in liquid nitrogen prior to RNA extraction (RNeasy Lipid Tissue
Mini Kit, QIAGEN, MD, USA), labeling and hybridization to Affymetrix
Canine Genome 2.0 arrays. Superﬁcial and deep frontal cortex samples
for immunohistochemistry were ﬁxed in 10% neutral buffered
formalin or 2.5% glutaraldehyde before undergoing routine processing
and embedding in parafﬁn or Spurrs resin blocks.
2.2. Microarray analysis
Probe set intensities were preprocessed with GeneChip® Operat-
ing Software prior to analysis using BioConductor packages in R [18].
This included robust multi-array (RMA) normalization with affy [19]Table 1
Treatment groups for the intracisternal enzyme replacement therapy trial.
Animal Treatment
CVT.1
t
PBS vehicle (150 μl)
CVT.2
CVT.3
AET.1
t
Recombinant canine α-L-fucosidase (0.96 mg/dose in 150 μl of PBS)
AET.2
AET.3
AVT.1
t
PBS vehicle (150 μl)
AVT.2
AVT.3
CVT: unaffected vehicle treated control, AET: fucosidosis-affected enzyme treated, AVT:
fucosidosis-affected vehicle treated control.and differential gene expression analysis with limma [20]. Probes with
an adjusted Pb0.05 were considered to be differentially expressed
and were further analyzed using Ingenuity Systems Pathway Analysis
(IPA) to identify functional groups. Gene Set Enrichment Analysis
(GSEA) was also performed as previously described [21] using the
gene set permutation method and a signiﬁcance level of Pb0.01 and a
FDRb0.05. GSEA uses the entire gene expression proﬁle generated
and was performed to identify biological pathways which may be
involved in fucosidosis pathogenesis but not necessarily detected
using differential gene expression alone.
2.3. Quantitative reverse transcriptase PCR (qRT-PCR)
Five genes from the DE gene lists and the GSEA results were
selected for further analysis and comparison with the microarray
results using qRT-PCR. Selected genes were chosen due to their
involvement in neuropathological processes and included BCL2 to
represent apoptosis pathways, LIMP2 to represent lysosomal function,
CNP MAL and PLP1 for their involvement in oligodendrocyte and
myelin development. GAPDH and PPIAwere used as internal controls.
Oligonucleotide primers (Table 2) were designed from reference
sequences obtained from GenBank using Primer3 [22]. RNA was
extracted as previously described and cDNA was synthesized from
2 μg of total RNA using reverse transcriptase (SuperScriptIII, Invitro-
gen, CA, USA) and oligo (dT) primer (Invitrogen). PCRs were
performed using a Rotor-Gene 6000 (QIAGEN, MD, USA) real-time
thermal cycler under the following conditions; initial denaturation at
95 °C for 5 min followed by 35 cycles of 95 °C for 30 s, 60 °C for 60 s
and 72 °C for 60 s in the presence of 1.5 mM MgCl2 and 2 μM of
SYTO9® ﬂuorescent dye (Invitrogen).
2.4. Immunohistochemistry
Sections of superﬁcial and deep cerebral cortex from all dogs were
cut at 5 μm thickness for parafﬁn or 0.1 μm for resin embedded
sections and placed onto plain or silanized slides. Histochemical stains
included luxol fast blue with periodic acidic Schiff (LFB/PAS) and
toluidine blue. Immunostains were CNPase (monoclonal mouse anti-
CNPase, Millipore, Temecula, CA, USA, 1:400), GFAP (polyclonal rabbit
anti-GFAP, Dako, Glostrup, Denmark, 1:2000), IL6 (monoclonal mouse
anti-IL6, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:200) and
Ricinus communis agglutinin-1 lectin (RCA-1, Vector Laboratories,
Burlingame, CA, USA, 1:2500). Staining for GFAP and RCA-1 was
performed as described in Ref. [8]. The remaining slides, after
deparafﬁnization and rehydration, underwent heat induced antigen
retrieval at pH 6 (Target Retrieval Solution pH 6, Dako) before
blocking endogenous peroxidase activity with 3% hydrogen peroxide
in PBS. CNPase staining was performed with an automated stainingPrimer Sequence (5′ to 3′) Product size (bp)
BCL2 (+) GACTTCTCCCGCCGCTAC
BCL2 (−) GGTTGACGCTCTCCACACAC 184
CNP (+) CCCAGCTCAAGGAGAAGAAC
CNP (−) TCAGGAACCAGCCGAAGTAG 108
GAPDH (+) GCCAAAAGGGTCATCATCTC
GAPDH (−) GGGGCCATCCACAGTCTTCT 228
LIMP2 (+) TCCCTCGGTTAGAAGAAGTGG
LIMP2 (−) TCCCGAAAGAAGTGAAGATGG 223
MAL (+) CGGACCTGCTCTTCATCTTC
MAL (−) AACACAGACACAAACATCACCC 115
PLP1 (+) CTGGCTGAGGGCTTCTACAC
PLP1 (−) CAGCAGAGCAGGCAAACAC 256
PPIA (+) ATGGATGGCGAGCCTTTG
PPIA (−) CTTTTCCCCGTAGATGGACTTG 213
(+) Forward primer, (−) reverse primer.
Fig. 1. DE gene expression and pathway analysis.
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Mini kit (Dako) for mouse antibodies. IL6 was performed manually;
blocking with normal horse serum occurred before overnight
incubation with the primary antibody at 4 °C. Slides were then
incubated with biontinlyated horse anti-mouse antibody and an
avidin–biotin peroxidase substrate (Vectastain Elite ABC kit, Vector
Laboratories). All slides were visualized with 3,3-diaminobenzidine
(DAB) substrate and counterstained with hematoxylin. An Apoptag
Peroxidase In Situ kit (Millipore) utilizing the in situ deoxynucleotide
transferase mediated dUTP nick-end labeling (TUNEL) method was
used to detect apoptosis following the manufacturer's instructions.
3. Results
3.1. Differential gene expression
The changes in gene expression identiﬁed by microarray analysis
reﬂected the complex neuropathology observed in the frontal cortex
of affected dogs. No probes or genes were signiﬁcantly differentially
expressed (DE) between fucosidosis AET and AVT dogs (Fig. 1).
Comparison of the DE probe lists generated from contrasting the gene
expression proﬁle of the frontal cortex from AET against that from CVT
dogs (AET vs. CVT, Appendix A) and from comparing the expression
proﬁle from AVT to CVT (AVT vs. CVT, Appendix B) revealed that there
were 226 probes common to both lists, 86 probes unique to the AET
vs. CVT contrast and 196 probes unique to the AVT vs. CVT contrast.
Excluding probes that mapped to expressed sequence tags (ESTs) and
collapsing multiple probes that mapped to a single gene, this
corresponded to 136 commonly DE genes, 44 DE genes unique to
AET vs. CVT and 107 DE genes unique to AVT vs. CVT (Fig. 1). The
genes common to both lists were DE in the same direction with 83
genes upregulated and 53 genes downregulated in affected animals
regardless of treatment when compared to unaffected controls. IPA
pathway analysis of the commonly DE genes classiﬁed 33% as having a
role in inﬂammation, 33% in cell signaling, 32% in hematological
system development and function, and 18% having a role in calcium
metabolism (Fig. 1). Upregulated genes associated with inﬂammation
include members of the dog MHC class II complex, and genes for
complement factors and cathepsins (Appendices A and B). Many
genes involved in calcium metabolism were upregulated relative to
the control including apolipoprotein E (APOE), alpha-2-macroglobulin
(A2M), v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
(LYN) and spleen tyrosine kinase (SYK; Appendices A and B). LysosomalFig. 2. GSEA and qRT-PCR. (A) GSEA heat map of Hydrolase Sardiello geneset, red = up
compared to microarray detected changes. Gene expression is expressed as fold change rela
(E) microglia, (F) OL speciﬁc and (G) myelin sheath genesets, red = upregulated, blue = dgeneswere also signiﬁcantly upregulated (Appendices A andB) including
MAN2B1 encoding α-mannosidase and GUSB encoding β-glucuronidase.
As expected, the gene encoding α-L-fucosidase, FUCA1 was the most
signiﬁcantly DE gene in both lists (Pb0.001, Appendices A andB) andwas
not expressed due to the 14 bp deletion in FUCA1 that causes canine
fucosidosis [2].
Commonly downregulated genes relative to the control involved
in the formation and maintenance of stable compact myelin included
ASPA, CNP, MAG, MAL and OPALIN (Appendices A and B). These genes
encode aspartoacylase, 2′, 3′-cyclic nucleotide 3′ phosphodiesterase,
myelin-associated glycoprotein, myelin and lymphocyte protein and
OL myelin paranodal and inner loop protein respectively. Additional
myelin genes were only downregulated in the AVT vs. CVT contrast
and included myelin oligodendrocyte glycoprotein (MOG), myelin-
associated OL basic protein (MOBP), OL speciﬁc protein/claudin-11
(OSP/CLDN11) and the canine homolog to the recently identiﬁed
myelin regulatory factor [13], LOC483794 which shares 85% identity
with MRF (Appendix B).
More inﬂammation and immune-related genes were DE in the AVT
vs. CVT contrast with 21% of signiﬁcantly DE genes unique to AVT vs.
CVT involved in inﬂammatory pathways, compared to 16% of
signiﬁcantly DE genes unique to AET vs. CVT. In addition, 23% of DE
genes unique to the AVT vs. CVT contrast were classiﬁed as involved in
cell signaling and 20% in hematological system development and
function (Fig. 1).
20% of signiﬁcantly DE unique to the AET vs. CVT contrast were
involved in cell death pathways and featured the upregulation of toll-
like receptor 4 (TLR4; Appendix A), known to have a key role in
priming the inﬂammatory response in MPS IIIB [23], VI and VII [24].
23% of signiﬁcantly DE genes unique to AET vs. CVT were also
classiﬁed to be involved in cell signaling and 23% in hematological
system development and function, and 18% in nervous system
development and function (Fig. 1).
3.2. Geneset enrichment analysis (GSEA)
Since there were no signiﬁcantly DE genes between fucosidosis
AET and AVT dogs, all affected dogs were grouped as ‘affected’
regardless of treatment for GSEA.
3.2.1. Lysosomal genes
Lysosomal genesets were signiﬁcantly enriched in affected dogs.
The Hydrolase Sardiello geneset consisting of lysosomal genes
containing the Coordinated Lysosomal Expression and Regulation
(CLEAR) element which are regulated by the transcription factor EB
[25] was highly signiﬁcantly enriched. This gene set included CTSC,
CTSD, CTSH and CTSS which encode cathepsins C, D, H and S, MAN2B1
and MANBA encoding α- and β-mannosidase, and HEXB encoding
β-hexosaminidase. NPC1 encoding Niemann Pick C1 protein and
FUCA1, also in this geneset, were decreased in affected dogs (Fig. 2A).
Glycosphingolipid membrane metabolism, phagocytosis, endosome
and secretory pathway genesets were not signiﬁcantly enriched in
either group (Table 3).
3.2.2. Inﬂammatory and apoptosis gene sets are upregulated
Increased expression of inﬂammatory genes in affected frontal
cortex was evident in the GSEA. Both the general inﬂammatory
response and apoptosis genesets were signiﬁcantly enriched in
affected dogs (Table 3). Genes that contributed to the enrichment
of the inﬂammatory geneset included interleukin 1α (IL1A), TNFregulated, blue = downregulated. (B) Normalized qRT-PCR gene expression changes
tive to control samples. GSEA heat maps of (C) HSA04120 apoptosis, (D) inﬂammation,
ownregulated.
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Table 3
GSEA results.
Gene set ES NES Source Size P-value FDR
Lysosomal and membrane function
Hydrolase Sardiello 0.696 2.259 [24] 62 b0.0001 b0.0001
Lysosome 0.629 1.935 Gene ontology 54 b0.0001 0.004
Endosomal transport 0.661 0.171 Gene ontology 20 0.016 0.018
Phagocytosis 0.595 1.406 Gene ontology 15 0.106 0.113
Endosome 0.352 1.128 Gene ontology 61 0.267 0.344
Secretory pathway 0.245 0.813 Gene ontology 73 0.803 0.75
HSA00600 sphingolipid metabolism −0.493 −1.554 BioCarta 34 0.025 0.069
Glycosphingolipid metabolism −0.471 −1.32 Gene ontology 21 0.143 0.125
Lipid raft 0.608 1.647 Gene ontology 23 0.016 0.046
HSA00604 glycosphingolipid biosynthesis ganglioseries 0.514 1.243 BioCarta 15 0.208 0.277
Membrane and lipid metabolic process 0.333 1.124 Gene ontology 86 0.281 0.296
Inﬂammation
Inﬂammation 0.591 2.054 Gene ontology 100 b0.0001 0.003
Microglia 0.71 2.007 Literature search 30 b0.0001 0.001
Astrocyte speciﬁc 0.628 1.746 [25] 30 0.005 0.017
Inﬂammatory response 0.495 1.739 Gene ontology 94 0.003 0.014
Cytokine production 0.524 1.649 Gene ontology 55 0.012 0.026
TNFR1 pathway 0.522 1.411 BioCarta 26 0.099 0.101
IL6 pathway 0.499 1.27 BioCarta 19 0.19 0.173
Apoptosis
TNFR2 pathway 0.473 1.178 BioCarta 17 0.281 0.229
Cysteine type peptidase activity 0.544 1.686 Gene ontology 46 0.003 0.068
Cysteine type endopeptidase activity 0.572 1.651 Gene ontology 36 0.013 0.052
HSA04210 apoptosis 0.505 1.648 BioCarta 73 0.006 0.035
Induction of apoptosis by extracellular signals 0.599 1.617 Gene ontology 26 0.024 0.033
Caspase pathway 0.587 1.54 Gene ontology 20 0.027 0.047
Neuron apoptosis 0.336 0.835 Gene ontology 16 0.687 0.815
Induction apoptosis by intracellular signals 0.287 0.739 Gene ontology 19 0.812 0.846
Oligodendrocyte and myelin
Oligodendrocyte speciﬁc −0.921 −2.647 [25] 23 b0.0001 b0.0001
Oligodendrocyte up −0.846 −2.616 [26] 34 b0.0001 b0.0001
Emery et al. 2009 −0.791 −2.41 [13] 30 b0.0001 b0.0001
Myelination −0.678 −2.288 Gene ontology 49 b0.0001 b0.0001
Myelin sheath −0.797 −2.067 Gene ontology 15 b0.0001 b0.0001
Oligodendrocyte differentiation −0.485 −1.491 Gene ontology 32 0.045 0.043
Oligodendrocyte down 0.551 1.621 [26] 42 0.016 0.018
ES: enrichment score, NES: normalized enrichment score, FDR: false discovery rate.
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(TGFB1), chemokine (C–C motif) receptor 1 (CCR1) and 5 (CCR5,
Fig. 2D). Genesets for microglia markers, and astrocyte speciﬁc genes
were signiﬁcantly enriched in both groups of affected dogs (Table 3).
Enriched microglial markers included several cathepsin genes (CTSH,
CTSL2, and CTSS) and CD antigens (CD14 and CD68, Fig. 2E). Genes that
contributed to the enrichment of the apoptosis geneset included the
Bcl-2 family genes, BAX, BCL2 and BID as well as caspases 8 (CASP8)
and 10 (CASP10, Fig. 2C). Genesets for TNFR1, TNFR2, IL6 and caspase
pathways, neuronal apoptosis, and induction of apoptosis by
intracellular signals and extracellular signals were not signiﬁcantly
enriched (Table 3).
3.2.3. Oligodendrocyte and myelin genes are downregulated
All but one OL development and myelination geneset were highly
signiﬁcantly downregulated in fucosidosis dogs with a negative
enrichment score (Table 3). In addition to identifying decreased
expression in CNP, MAG, MAL, MOBP, MOG, OPALIN and OSP/CLDN11,
GSEA identiﬁed MBP and PLP1 to be downregulated in fucosidosis
dogs (Fig. 2F and G). These genes encode the major myelin structural
proteins, myelin basic protein and proteolipid protein 1. Almost all OL
speciﬁc geneset members which are speciﬁcally upregulated in OLs
[26] were decreased in fucosidosis dogs. The geneset downregulated
during OL development, OL down, was the only myelin related
geneset to have signiﬁcant positive enrichment in affected cortex
(Table 3).3.3. qRT-PCR
Microarray gene expression changes detected by DE and GSEA
analyses were closely matched by qRT-PCR results with increased
expression of BCL2 and LIMP2 and decreased expression of CNP, MAL
and PLP1 (Fig. 2B).
3.4. Neuropathology
Detailed characterization of neuropathology, including improve-
ments due to IT-ERT, have been reported elsewhere [7,8,16]
(Kondagari, unpublished data). Brieﬂy, lysosomal storage and
vacuolation was well established in the superﬁcial and deep frontal
cortex and affected the cytoplasm of neurons, astrocytes and
microglia (Fig. 3B) of fucosidosis dogs. Inﬁltration, enlargement
and extensive cytoplasmic vacuolation of RCA-1 lectin positive
microglia and perivascular macrophages were increased in the
frontal cortex of affected dogs (Fig. 3D) and enlarged swollen GFAP
positive astrocytes with extensive processes were also present
(Fig. 3F). These astrocytes are consistent with upregulation of GFAP
detected in the astrocyte speciﬁc geneset during GSEA and in the DE
gene list of genes unique to the AET vs. CVT contrast. Neuroin-
ﬂammatory pathology appeared to be more severe in AVT dogs
compared to AET dogs. In addition, cytoplasmic staining of IL6 in
neurons was darker and less diffuse in affected dogs validating the
relative upregulation of IL6 detected in the inﬂammation gene sets
Fig. 3. Neuropathological changes in the frontal cortex of fucosidosis-affected dogs compared to unaffected controls. All dogs from each group (CVT, AVT and AET, n=3) were
examined, and representative photomicrographs from CVT and AVT are shown here. Toluidine blue semi-thin sections from (A) control and (B) affected dogs showing neuronal
vacuolation (▲). RCA-lectin stained sections from (C) control and (D) affected dogs, brown staining indicates microglia (▲). GFAP stained sections from (E) control and (F) affected
dogs showing activated astrocytes with elongated processes (▲). IL6 staining of (G) control and (H) affected cortex. Cerebrocortical white matter stained with LFB/PAS: (I) control,
(J) affected, and CNPase: (K) control and (L) affected. Apoptag TUNEL sections from (M) control and (N) affected dogs, brown stained nuclei with membrane blebbing and/or cell
shrinkage are apoptosis positive (▲). A, B, I–L, all 1000× magniﬁcation, C–H, M, N, all 400× magniﬁcation.
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with decreased intensity of LFB stained white matter tracts (Fig. 3J).
OLs showed limited vacuolation in semi-thin sections in contrast to
extensive vacuolation of other glial cell types. CNPase staining wasreduced in white matter tracts of affected dogs with fewer CNPase+
nuclei (Fig. 3L) consistent with decreased CNP gene expression and
indicative OL loss. Apoptag TUNEL positive neurons and glial cells
with membrane blebbing and cell shrinkage were prominent in
Fig. 4. Proposed model of fucosidosis pathogenesis.
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fucosidosis-affected dogs.
4. Discussion
Gene expression changes identiﬁed by microarray analysis of the
frontal cortex in fucosidosis-affected pups reﬂect the complex
neuropathology present early in disease, and suggest a model of
pathogenesis consistent with early hypomyelination in fucosidosis. A
proposed model is shown in Fig. 4; deﬁciency of α-L-fucosidase
results in lysosomal storage, cytoplasmic vacuolation of neurons and
glia and the upregulation of lysosomal genes, such as MAN2B1 and
GUSB. Upregulation of lysosomal genes occurs in other LSDs including
mucolipdosis IV [17] and MPS VI [27] and may be an attempt to
enhance the lysosomal system and overcome storage [25]. However,
accumulation of substrates also triggers an early inﬂammatory response
which in fucosidosis recruits astrocytes and microglia that may secrete
pro-apoptotic mediators such as IL1A and CTSS, as suggested by the
increased expression of these genes. This triggers extracellular signals
that initiate apoptosis of neurons and glia demonstrated in the apoptag
TUNEL staining and as indicated by increased expression of TNFRSF1A,
CASP8 and Bcl-2 family genes. Secretion of pro-apoptotic mediators by
glial cells has been demonstrated in other LSDs [9,28] and CTSS, CTSD,
TNFRSF1A, CASP8, BID and BAX are well characterized initiators of
apoptosis [29–31]. Apoptotic depletion of neurons occurs in preclinical
disease [7] during a critical stage of CNS development and potentially
contributes to the myelin deﬁcits in fucosidosis by reducing axonal
electrical signals required for oligodendrocyte maturation and the
production of stable compact myelin [14,32,33].
Neuropathology studies of canine fucosidosis have demonstrated
that vacuolation, neuroinﬂammation, neuronal apoptosis and myelin
losses are present by 4 months of age, well before the onset of clinical
signs [7,8] and during a critical period of CNS development. The
decreased expression of CNP, MAG, MAL, and OPALIN and reduction of
CNPase+ nuclei in the white matter tracts of the cerebral cortex of
fucosidosis-affected dogs regardless of treatment at 4 months, when
postnatal development is continuing in the dog [34], suggests that
lysosomal dysfunction contributes to hypomyelination by impairing the
cellular development of OLs. Reduced OL maturation leading to thedecreased OL numbers demonstrated by CNPase stainingwould explain
the signiﬁcant negative enrichment of OL speciﬁc genesets and
downregulation of OL speciﬁc genes. Decreased expression of CNP,
MAG and PLP1were revealed by Northern blot hybridization in another
glycoprotein LSD, caprine β-mannosidosis, where OL loss also occurs
[35,36]. In caprine β-mannosidosis, OL loss is accompanied by
substantial, early OL vacuolation [35]. In contrast, OLs showed mild,
inconsistent vacuolation in untreated fucosidosis-affected dogs. Species
differences in the onset and completion of myelinationmay account for
this difference in the extent of OL vacuolation and loss withmyelination
nearly complete at birth in precocial goats [37] compared to the
continuing postnatal development of myelin in altricial dogs. The direct
mechanism of OL loss and the role of lysosomal storage requires further
investigation in both neonatal caprine β-mannosidosis and canine
fucosidosis.
Downregulation of myelin sheath and OL-speciﬁc genes in
4 month-old canine fucosidosis-affected brain may be due to the
signiﬁcant neuron loss that is evident at this preclinical stage of
disease [7,8]. Early loss and vacuolation of neurons would impair and
reduce transmission of electrical impulses required for OL prolifera-
tion and development, including the initiation of myelin gene
expression [14,38,39]. It has been shown that blocking electrical
activity by injection of tetrodotoxin into the rat optic nerve during
postnatal development reduced the population of OL precursor cells
by 80% [14]. It follows that a diminished population of developing OLs
would lead to decreased expression of OL and myelin-speciﬁc genes
andmyelin deﬁcits such as those seen in fucosidosis. That myelin gene
expression and CNPase+ nuclei were reduced in both AVT and AET
treated animals indicates that the mechanism causing fucosidosis
hypomyelination is engaged very early by 16 weeks of age [16].
Vacuolation induced neuronal deformity occurs during the rapid
postnatal myelination phase in the dog [7,8,34] and the consequences
of this on OLs and other glia is not understood.
Positive Apoptag TUNEL stained neurons in preclinical fucosidosis
conﬁrm and provide a mechanism for the signiﬁcant neuron loss
previously observed [7,8]. In the LSD, Sandhoff disease, positive
Apoptag TUNEL neuronswere found in the spinal cord, brain stem and
thalamus of early clinical disease [9]. The apoptosis was associated
with increased expression of TNFα in these areas of diseased brain [9].
TNFα was unaltered in fucosidosis, however increased expression of
TNFRSF1A, CASP8, CASP10, BID, BAX and BCL2 contributed to signiﬁcant
enrichment of the HSA04210 apoptosis geneset. These genes are
involved in the initiation of apoptotic pathways via extrinsic cell death
signals [29]. Upregulation of TNFRSF1A and CASP8 in fucosidosis
cerebral cortex supports neuroinﬂammation as the trigger initiating
apoptotic neuron loss.
Neuroinﬂammation is a major component of canine fucosidosis with
33% of commonly signiﬁcant DE genes having a role in inﬂammatory
pathways and cell signaling. This corresponds to the observedwidespread
inﬁltration of microglia and perivascular macrophages in the cerebral
cortex of 4 month old pups. This early inﬂammation is a response to the
cellular damage caused by storage and lysosomal enlargement, and it has
previously been found that as fucosidosis progresses, so does the
activation of astrocytes andmicroglia [7,8]. Such chronic neuroinﬂamma-
tion has been established to have neurotoxic effects in other neurode-
generative diseases [40] and LSDs such as Sandhoff [9] and Gaucher
diseases [28]. Chronic inﬂammatory neurotoxicity results from secretion
of proinﬂammatory cytokines suchasTNFα, IL8and IL1αbymicroglia and
astrocyteswhich trigger extrinsic apoptotic pathways causing neuron loss
[40,41]. Signiﬁcant enrichment of inﬂammation and apoptosis genesets,
along with increased expression of IL1A and other genes encoding pro-
apoptotic inﬂammatorymediators including CTSS suggests that apoptosis
triggered by neuroinﬂammation is an important mechanism of neuron
loss in canine fucosidosis.
While there were no signiﬁcantly DE genes between AET and
AVT animals there were indications of reduced upregulation of
1425J.L. Fletcher et al. / Biochimica et Biophysica Acta 1812 (2011) 1418–1426inﬂammatory genes in the frontal cortex of AET dogs, with 21% of
signiﬁcantly DE genes unique to AVT vs. CVT classiﬁed as involved in
inﬂammatory and immune functions compared to 16% of DE unique to
AET vs. CVT. This is consistent with neuropathology ﬁndings where
there appeared to be reduced neuroinﬂammatory pathology in AET
compared to AVT dogs. (Kondagari, unpublished data). It is likely that
IT-ERT did not have an effect on global gene expression due to the
treatment protocol. Low dose infusion was administered monthly
from 2 to 4 months [16] and this does not appear to be early or
frequently enough to have a signiﬁcant positive impact on neuroin-
ﬂammatory pathology (Kondagari, unpublished data) or gene
expression.
The gene expression microarray results have provided further
insight into the processes involved in the early stages of fucosidosis
storage pathology. Upregulation of lysosomal, inﬂammation and
apoptosis genes is consistent with the vacuolation, microglial
inﬁltration and neuronal apoptosis observed in the affected cerebral
cortex. These ﬁndings link the neuroinﬂammatory processes that
contribute to fucosidosis neuronal loss to pathways triggering
extracellular apoptosis. Decreased expression of OL and myelin-
speciﬁc genes and reduced CNPase staining at 4 months when myelin
deﬁcits and OL vacuolation are subtle provides evidence that
fucosidosis myelin loss is due to a failure in myelin development
processes, possibly through reduced electrical impulses caused by
neuron loss. This proposed model of fucosidosis pathogenesis links
fucosidosis storage changes and provides a framework for further
investigation of pathogenic mechanisms in fucosidosis.Role of funding source
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